REGENERON PHARMACEUTICALS, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Regeneron reported Q2 2026 revenues of $4.3B (+17% YoY), with GAAP EPS of $12.23 and non-GAAP EPS of $14.29. Key drivers: Dupixent global sales hit $6.0B (+38%), EYLEA HD U.S. sales reached $596M (+52%), and Libtayo global sales climbed to $489M (+30%). The company fully repaid its $2B+ Sanofi Development Balance by quarter-end, unlocking meaningful profit-share increases starting Q3 2026. Pipeline includes ~50 clinical assets; cemdisiran regulatory submissions accepted by FDA and EMA for generalized myasthenia gravis.
Why this rating
Strong Q2 execution with double-digit top/bottom-line growth and Sanofi debt repayment unlock future margin expansion. However, EYLEA legacy decline (-45% U.S., -21% total) and fianlimab Phase 3 miss offset optimism. Event material but not transformational for $54.8B company.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.